CelLBxHealth plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ANPCY research report →
Price Chart
About the company
CelLBxHealth plc is a medical diagnostics firm specializing in the creation of cancer detection solutions, with operations spanning the United Kingdom, broader Europe, North America, and other global markets. A flagship offering is the Parsortix PC1 system, a medical device engineered to isolate and collect whole circulating tumor cells (CTCs) from the blood of patients with metastatic breast cancer, preparing them for further user-validated analysis. The company also provides the Parsortix PR1 system for general CTC capture and collection from blood samples.
- CEO
- Peter Collins
- IPO
- 2015
- Employees
- 119
- HQ
- Guildford, GB
Get TickerSpark's AI analysis on ANPCY
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
Latest fiscal year · YoY change
- Revenue
- $2.86M+30.9%
- Gross Profit
- $1.78M+536.0%
- Op Income
- $-15,096,000
- Net Income
- $-14,225,000+29.3%
- EPS
- $-0.48+37.6%
- OCF Growth
- +7.0%
- FCF Growth
- +8.1%
- 52W High
- $2.39
- 52W Low
- $0.07
- 50D MA
- $0.18
- 200D MA
- $0.63
- Beta
- 0.14
- RSI (14)
- 35
- Avg Volume
- 19.15K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ANGLE said commercialization advanced strongly in H1 2025, but revenue was pressured by a difficult market and delayed customer decisions.· September 9, 2025
- 3 major H1 achievements: completed 3 large pharma projects, advanced Illumina-based DNA dual analysis, and published cluster-cancer findings in Nature Medicine.
- Revenue was under pressure from market conditions; pharma revenue declined year over year and product revenue was flat.
- Operating expenditure fell 12% year over year, helping reduce comprehensive loss by 7%.
- Cash and R&D tax credits were GBP 6.6 million, with runway unchanged into Q1 2026.
- New Myriad Genetics collaboration and NHS discussions could broaden commercialization if they progress.
ANGLE did not give a numeric revenue or EPS figure in the prepared remarks, but management said H1 pharma revenue was down versus the prior year and product revenue was flat. Operating expenditure was reduced by 12% year over year, and comprehensive loss fell by 7%. Cash and R&D tax credits stood at GBP 6.6 million, with cash runway unchanged into Q1 2026. Management did not provide formal next-quarter or full-year revenue guidance, but said it expects further progress from large pharma, medtech, and NHS discussions, while also noting the need to raise additional funding in H2 through a combination of revenue, commercial milestones, licensing, collaboration income, debt, or equity.
Andrew Newland framed the half as a mix of major commercial progress and difficult trading conditions. He highlighted completed pharma assays with Eisai and AstraZeneca, the Illumina end-to-end DNA dual-analysis workflow, the Nature Medicine cluster-cell publication, and the Myriad Genetics collaboration as evidence that ANGLE is moving toward broader adoption. His tone was optimistic about long-term opportunity, especially with medtech, pharma, and the NHS, but he acknowledged that deal timing is outside the company’s control and that H2 funding remains a priority.
Ian Griffiths emphasized tight cost control and the need to keep delivering milestones. He said operating spend has been managed down, with some spend paused or cut back, but that a regulated business still requires a baseline level of capability and capacity. He also noted that funding options include commercial milestones, licensing, collaboration income, debt, and equity, and said the company will likely need to raise additional funding through one or more of those routes.
Analysts asked whether market headwinds were easing, how meaningful NHS clinical studies could be, and whether peer-reviewed publications were helping business development. Management pointed to the Myriad deal and rising interest in multi-omics as encouraging signs, said NHS work may begin as a pilot in lung cancer patients, and confirmed that publications are actively used in BD outreach. Questions also focused on the next stage for completed Eisai and AstraZeneca projects, with management saying large pharma controls the timing and that visibility on follow-on contracts remains limited, though interest is increasing. On Myriad, management said near-term work is paid service work, with future upside from clinical studies, Parsortix machines, laboratories, and consumables at $300 per cassette.
The call showed multiple commercialization paths gaining traction: pharma assays, a first large medtech collaboration, NHS engagement, and lab accreditation that could let ANGLE offer tests directly. Management also emphasized that Parsortix has a growing body of evidence, with 46 cancer centers in 15 countries and 115 peer-reviewed publications across 23 solid tumors.
The main near-term risk is commercial timing: management said large pharma and medtech decisions have been delayed by market volatility, tariff concerns, and weak capital access for smaller customers. Revenue was under pressure in H1, and the company said it will likely need additional funding in H2, with cash runway only into Q1 2026.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 68.8%
- Shares Outstanding
- 32.80M
- Float Shares
- 22.55M
Our ANPCY coverage
Recent articles, reports, and earnings notes.
No research on ANPCY yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ANPCY report →T. ROWE PRICE LAUNCHES SEASON 6 OF "THE ANGLE" PODCAST SERIES WITH INVESTOR-FOCUSED LOOK AT AI ADOPTION
prnewswire.com · Jul 1
CelLBxHealth shares rise 8% on Royal Marsden lung cancer collaboration
proactiveinvestors.co.uk · Apr 20
CelLBxHealth joins forces with The Royal Marsden on lung cancer liquid biopsy study
proactiveinvestors.co.uk · Apr 20
CelLBxHealth shares rise 3% as company continues to focus on cost base
proactiveinvestors.co.uk · Feb 13
CelLBxHealth drops FDA device listing to cut costs and refocus on revenue growth
proactiveinvestors.co.uk · Feb 13
CelLBxHealth backed for rebound by broker
proactiveinvestors.co.uk · Jan 16
CelLBxHealth enters 2026 with strong pipeline
proactiveinvestors.co.uk · Jan 16
CelLBxHealth Health confirms boardroom appointments
proactiveinvestors.co.uk · Jan 12
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.